The basic principles of immunosuppressive therapy after kidney transplantation
https://doi.org/10.23873/2074-0506-2018-10-1-42-49
Abstract
The article deals with medical and organizational issues of individually-adapted immunosuppressive therapy in renal allograft recipients. In the recent years, the basis of nephroprotective therapy schemes includes m-TOR inhibitors. The accessibility of these drugs for those in need is limited. Meanwhile, a more widespread use of these drugs in clinical transplantation would both increase the life span of a transplanted kidney, and reduce the risk of viral infections and cancer in the long-term after kidney transplantation, and would also allow a rational use of budget funds for the treatment of such patients.
About the Author
D. N. Suslov
Russian Scientific Center of Radiology and Surgical Technologies n.a. acad. A.M. Granov
Russian Federation
Cand. Med. Sci., Head of the Experimental Surgery Group
Russian Federation
Cand. Med. Sci., Head of the Experimental Surgery Group
References
1. Drug monitoring and interchangeability of original and generic, immunodepressive drugs with narrow therapeutic index. National clinical guidelines. Mos-cow, 2014. 23 p.
2. Kuypers D.R. Benefit-risk assessment of sirolimus in renal transplantation. Drug Saf. 2005;28(2):153–181. PMID:15691225
3. Halloran P.F. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351(26):2715–2729. PMID:15616206 DOI:10.1056/NEJM-ra033540
4. Heemann U., Viklicky O. The role of belataceptin transplantation: results and implications of clinical trials in the context of other new biological immunosuppressant agents. Clin Transplant. 2013;27(1):E3-11. PMID:23199344 DOI:10.1111/ctr.12044
5. Opelz G., Dohler B. Influence of Immunosuppressive Regimens on Graft Survival and Secondary Outcomes after Kidney Transplantation. Transplantation. 2009;87(6):795–802. PMID:19300179 DOI:10.1097/TP.0b013e318199c1c7
6. Morris P.J. Transplantation – a medical miracle of the 20th century. N Engl J Med. 2004;351(26):2678–2680. PMID:15616201 DOI:10.1056/NEJMp048256
7. Campbell S., McDonald S., Chang S., et al. Chapter 8. Transplantation. In: McDonald S., Chang S., Excell L., eds. ANZDATA registry report 2007. Adelaide, South Australia: Australia and New Zealand Dialysis and Transplant Registry, 2007.
8. Jain K.K. From molecular diagnostics to personalized medicine. The IBC Workshop, London, UK, 1st May, 2002. Exp Rev Mol Diagn. 2002;2(4):299–301. DOI:10.1586/14737159.2.4.299
9. On the circulation of medicines. Federal Law of 12.04.2010, № 61FL. November 25, 2013 ed. Available at: https://normativ.kontur.ru/document?moduleI d=1&documentId=304074
10. Dal' V.I. Explanatory dictionary of the living Great Russian language: in 4 volumes. Moscow: Russkiy yazyk Publ., 1978-1980.
11. Yurgel' N.V., Tel'nova E.A. ADS – PNM, "7 nosologies," and then what? Vestnik Roszdravnadzora. 2008;(5):4–21. Available at: http://www.remedium.ru/ public/journal/vr/2008/VR_05_2008.pdf
12. Pascual J., Boletisb J.N., Campistolc J.M. Everolimus (Certican) in renal transplantation: a review of clinical trial data, current usage, and future directions. Transplant Rev. 2006;20(1):1–18. DOI:10.1016/j.trre.2005.10.005
13. Ormiston J.A., Serruys P.W., Regar E., et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB) a prospective open-label trial. Lancet. 2008;371(9616):899–907. PMID:18342684 DOI:10.1016/S0140-6736(08)60415-8
14. Ponticelli C. Can mTOR inhibitors reduce the risk of late kidney allograft failure? Transpl Int. 2008;21(1):2–10. PMID:17635837 DOI:10.1111/j.1432-2277.2007.00524.x
15. Cruzado J.M. Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors. Transplant Rev. (Orlan-do). 2008;22(1):73–81. PMID:18631860 DOI:10.1016/j.trre.2007.09.003
16. Contreras A.G., Dormond O., Edelbauer M., et al. mTOR-understanding the clinical effects. Transplant Proc. 2008;40(10 Suppl):S9–S12. PMID:19100913 DOI:10.1016/j.transproceed.2008.10.011
17. Hudes G.R. Targeting mTOR in renal cell carcinoma. Cancer. 2009;115(10 Suppl):2313–2320. PMID:19402072 DOI:10.1002/cncr.24239
18. Eisen H. Long-term cardiovascular risk in transplantation--insights from the use of everolimus in heart transplantation. Nephrol Dial Transplant. 2006;21(Suppl 3):iii9–13. PMID:16815858 DOI:10.1093/ndt/gfl295
19. Schuler W., Sedrani R., Cottens S., et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation. 1997;64(1):36–42. PMID:9233698
20. Guba M., Pratschke J., Hugo C., et al. Early conversion to a sirolimus-based, calcineurin-inhibitor-free immunosuppression in the SMART trial: observational results at 24 and 36months after transplantation. Transplant Int. 2012;25(4):416–423. PMID:22320241 DOI:10.1111/j.1432-2277.2012.01432.x
21. Guba M., Pratschke J., Hugo C, et al. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial. Transplantation. 2010;90(2):175– 183. PMID:20463641 DOI:10.1097/ TP.0b013e3181e11798
22. Jun H., Kim M.G., Jung C.W. Clinical advantages including medication adheren ce with conversion to once-daily advagraf and sirolimus combination in stable kidney recipients. Int J Clin Pharmacol Ther. 2016;54(2):81–86. PMID:26709601 DOI:10.5414/CP202518.
23. Hariharan S., McBride M.A., Cherikh W.S., et al. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int. 2002;62(1):311–318. PMID:12081593 DOI:10.1046/j.1523-1755.2002.00424.x
Review
For citations:
Suslov D.N. The basic principles of immunosuppressive therapy after kidney transplantation. Transplantologiya. The Russian Journal of Transplantation. 2018;10(1):42-49. https://doi.org/10.23873/2074-0506-2018-10-1-42-49
Views:
1628
